National Institute of Allergy and Infectious Diseases Archives
Study explores role RSV plays in later asthma development
Jul. 21, 2022—A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development
Study to explore neurologic impact of flu treatment
Feb. 24, 2022—A Vanderbilt study will explore the neurologic and psychiatric complications of flu and evaluate adverse effects of the antiviral treatment oseltamivir, also known by the brand name Tamiflu.
Fauci shares lessons learned during pandemic response with Vanderbilt MPH students
May. 12, 2021—Anthony Fauci, MD, chief medical adviser to President Joe Biden’s administration and director of the National Institute of Allergy and Infectious Diseases (NIAID), recently met virtually with students of Vanderbilt University School of Medicine’s Master of Public Health (MPH) program to answer questions about lessons learned during the pandemic and to share career advice.
Clinical Trials Unit lands major grant renewal
Feb. 11, 2021—Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.
Clinic uses new weapon to treat high-risk COVID patients
Dec. 17, 2020—Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.
Remdesivir helps reduce COVID-19 recovery time: study
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
Inflammation relief: what’s the delay?
Jun. 28, 2011—New research offers hope for patients needing the anti-inflammatory benefits of glucocorticoids without the adverse side effects associated with them.
